

Date: 9<sup>th</sup> April, 2018

To,  
The Manager,  
Listing Department  
National Stock Exchange of India Ltd  
'Exchange Plaza'  
Bandra Kurla Complex, Bandra (E),  
Mumbai – 400 051

Dear Sir/Madam,

**Sub: Alembic Pharmaceuticals Limited receives USFDA Approval for Acyclovir ointment USP, 5%.**

With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for Acyclovir ointment USP, 5%. Please find enclosed herewith our press release.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Alembic Pharmaceuticals Limited**



**R. K. Baheti**  
**Director - Finance & CFO**

Encl.: A/a.

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229  
website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN : L24230GJ2010PLC061123

## PRESS RELEASE

9<sup>th</sup> April, 2018, Vadodara, India

### **Alembic Pharmaceuticals receives USFDA Approval for Acyclovir ointment USP, 5%.**

Alembic Pharmaceuticals Limited today announced that the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Acyclovir ointment USP, 5%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Zovirax® ointment 5%, of Valeant Pharmaceuticals North America LLC. Acyclovir ointment USP, 5% is indicated in the management of initial genital herpes and in limited non-life-threatening mucocutaneous Herpes simplex virus infections in immunocompromised patients.

Acyclovir ointment USP, 5%, have an estimated market size of US\$ 145 million for twelve months ending December 2016 according to IMS.

Alembic now has a total of 71 ANDA approvals (63 final approvals and 8 tentative approvals) from USFDA.


### **About Alembic Pharmaceuticals Limited**

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at <http://www.alembicpharmaceuticals.com/>; (Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APLLTD) (BSE: 533573)

For more information contact:

|                                                                               |                                                                                     |
|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Ajay Kumar Desai                                                              | Mitanshu Shah                                                                       |
| Phone: +91 22 - 306 11681                                                     | Phone: +91 265 - 3007630                                                            |
| Email: <a href="mailto:ajay.desai@alembic.co.in">ajay.desai@alembic.co.in</a> | Email: <a href="mailto:mitanshu.shah@alembic.co.in">mitanshu.shah@alembic.co.in</a> |



## **ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229  
website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN : L24230GJ2010PLC061123